

<u>Disclosures</u>	
Royalties	Invitae (ArcherDx)
SAB	PAIGE.AI, Repare therapeutics, Kinnate, Oncoclinicas Brasil



































































Predictions MRD testing in certain solid tumors (CRC for sure) will be standard in 3-5 years Early detection assays will be controversial, clinical utility and cost-benefit needs to be determined AI-based mutation prediction will not be stand-alone tools, but eventually added to "decision-support" digital imaging tools Functional drug screens remain as research